Dr. Maria Tektonidou, Associate Professor in Rheumatology, Medical School, National and Kapodistrian University of Athens, co-authored with Dr. Michael Ward, National Institutes of Health, Bethesda, USA, an invited editorial in the high impact journal “The Νew England Journal of Medicine” (Impact Factor: 74.699).
The editorial is a critical approach to the potential role of belimumab, a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator (Blys), as add-on treatment in lupus nephritis, one of the leading causes of morbidity, organ damage, and mortality among patients with Systemic Lupus Erythematosus.
https://pubmed.ncbi.nlm.nih.gov/32937052/
For further information please click here